Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Act

Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations is a phase 3, randomised interventional study registered as NCT07829549 by RemeGen Co., Ltd., with a registry enrolment figure of 540 participants, started 2026-09-30 and due to reach its primary completion in 2031-04. Interventions recorded: RC148 Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection; Tislelizumab Injection plus Pemetrexed Disodium for Injection and Carboplatin Injection. Conditions listed: Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations. Primary outcome: Progression-Free Survival assessed by BIRC per RECIST v1.1. Lung eligibility wording from the registry: "Histologically or cytologically confirmed locally advanced or metastatic NSCLC, not amenable to curative-intent therapy". Sites: China. No results are recorded here; the registry entry is the source.